ArticlePloS one2013
Highly efficient retrograde gene transfer into motor neurons by a lentiviral vector pseudotyped with fusion glycoprotein.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Molecular Engineering of Virus Tropism.International journal of molecular sciences · 2024Review
- Emerging trends in virus and virus-like particle gene therapy delivery to the brain.Molecular therapy. Nucleic acids · 2024Review
- Synaptic configuration and reconfiguration in the neocortex are spatiotemporally selective.Anatomical science international · 2024Review
- Techniques to Render Dendritic Spines Visible in the Microscope.Advances in neurobiology · 2023Article
- Lentiviral Vectors for Ocular Gene Therapy.Pharmaceutics · 2022Review
- Dissecting the Prefrontal Network With Pathway-Selective Manipulation in the Macaque Brain-A Review.Frontiers in neuroscience · 2022Review
- Maximizing lentiviral vector gene transfer in the CNS.Gene therapy · 2021Article
- Dual-Viral Transduction Utilizing Highly Efficient Retrograde Lentivirus Improves Labeling of Long Propriospinal Neurons.Frontiers in neuroanatomy · 2021Article
- Rabies Virus Pseudotyped with CVS-N2C Glycoprotein as a Powerful Tool for Retrograde Neuronal Network Tracing.Neuroscience bulletin · 2020Article
- Intramuscular Delivery of Gene Therapy for Targeting the Nervous System.Frontiers in molecular neuroscience · 2020Article
- Dissecting the Role of Subtypes of Gastrointestinal Vagal Afferents.Frontiers in physiology · 2020Review
- Gene Therapy for ALS-A Perspective.International journal of molecular sciences · 2019Review
- The Lentiviral Vector Pseudotyped by Modified Rabies Glycoprotein Does Not Cause Reactive Gliosis and Neurodegeneration in Rat HippocampusIranian biomedical journal · 2019Article
- Retrogradely Transportable Lentivirus Tracers for Mapping Spinal Cord Locomotor Circuits.Frontiers in neural circuits · 2018Article
- Genetic manipulation of specific neural circuits by use of a viral vector system.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Nonhuman Primate Optogenetics: Recent Advances and Future Directions.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Review
- Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.Molecular therapy. Methods & clinical development · 2017Article
- Improved Monosynaptic Neural Circuit Tracing Using Engineered Rabies Virus Glycoproteins.Cell reports · 2016Article
- Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Perspective on the Road toward Gene Therapy for Parkinson's Disease.Frontiers in neuroanatomy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of gene therapy techniques to introduce transgenes that promote neuronal survival and protection provides effective therapeutic approaches for neurological and neurodegenerative diseases. Intramuscular injection of adenoviral and adeno-associated viral vectors, as well as lentiviral vectors pseudotyped with rabies virus glycoprotein (RV-G), permits gene delivery into motor neurons in animal models for motor neuron diseases. Recently, we developed a vector with highly efficient retrograde gene transfer (HiRet) by pseudotyping a human immunodeficiency virus type 1 (HIV-1)-based vector with fusion glycoprotein B type (FuG-B) or a variant of FuG-B (FuG-B2), in which the cytoplasmic domain of RV-G was replaced by the corresponding part of vesicular stomatitis virus glycoprotein (VSV-G). We have also developed another vector showing neuron-specific retrograde gene transfer (NeuRet) with fusion glycoprotein C type, in which the short C-terminal segment of the extracellular domain and transmembrane/cytoplasmic domains of RV-G was substituted with the corresponding regions of VSV-G. These two vectors afford the high efficiency of retrograde gene transfer into different neuronal populations in the brain. Here we investigated the efficiency of the HiRet (with FuG-B2) and NeuRet vectors for retrograde gene transfer into motor neurons in the spinal cord and hindbrain in mice after intramuscular injection and compared it with the efficiency of the RV-G pseudotype of the HIV-1-based vector. The main highlight of our results is that the HiRet vector shows the most efficient retrograde gene transfer into both spinal cord and hindbrain motor neurons, offering its promising use as a gene therapeutic approach for the treatment of motor neuron diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.